Research is our passion

The working group


Head: Priv.-Doz. Dr. Sieghart Sopper

The immune system is an effective control system in the detection and elimination of malignant cells (immunosurveillance of tumors). In the phase of tumor progression, however, this mechanism fails. The tumor immunology team is therefore concerned with the interaction between the immune system and the tumor and examines the changes caused by cancer and tumor therapy. Based on these findings, different approaches are developed to eliminate negative regulators and to strengthen effector functions against the tumor.

Current projects:

ENEST1st study: Pharmacokinetics and Immune monitoring In patients with early chronic phase CML treated with frontline Nilotinib. (Novartis)

ALLIVE study: Immune monitoring of AML and MDS patients receiving allogeneic stem cell transplantation. (GWD_TUD)

Oncotyrol: Identification and targeting of ovarian cancer stem cells. (FFG) Improvement of tumor immune therapy by adoptive cell transfer of cblb-deficient hyperreactive immune cells. (FWF)

Intracellular routine assay for detection of  TKI-efficacy in CML patients. (ÖNB) Assessing the immune status and its relevance in non-small cell lung cancer patients. Genetically engineered immune cells expressing chimeric antigen receptor targeting HER2neu as tool to break tumor tolerance.

We need your support!
Donate now and help

The Tyrolean Cancer Research Institute has the goal to develope new cancer therapy concepts and to get them to clinical use. This ambitious achievement underlines the creative optimism wich inspires the whole initiative.
Head: Priv.-Doz. Dr. Sieghart Sopper


Lutz-Nicoladoni C, Wolf D, Sopper S. Front Oncol 2015, 5:58

Boesch M, Zeimet AG, Rumpold H, Gastl G, Sopper S, Wolf D. Stem Cells Transl Med. 2015, 4(9):1028-32

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D. J Clin Oncol 2017, 35(2):175-184

Boesch M, Zeimet AG, Fiegl H, Wolf B, Huber J, Klocker H, Gastl G, Sopper S, Wolf D. Oncoscience 2016, 3(3-4), 85-7, 10.18632

Boesch M, Sopper S, Zeimet AG, Reimer D, Gastl G, Ludewig B, Wolf D. Biochim Biophys Acta 2016, 1866(2):276-289

Kropshofer G, Sopper S, Steurer M, Schwinger W, Crazzolara R. Am J Hematol 2016, 91(9):E357-8

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S. Clin Cancer Res 2016, 22(16):4030-8

Boesch M, Sopper S, Wolf D. Oncologist 2016, pii:theoncologist.2016-0159

Wolf D, Sopper S, Pircher A, Gastl G, Wolf AM. Stem Cell Int 2015, 230(11)2598-605